Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-icap No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as the general partner, has invested in ACT Genomics Holdings Company Ltd. ("ACTG") (Head office: British Cayman Islands; Representative Director: Hua-Key Chen), a venture company that utilizes research results from Kyoto University.

Outline of this investment
It is known that each patient has different genetic mutations (gene deletions, insertions, single nucleotide substitutions, translocations, duplications, etc.) during the process of transformation of normal cells into cancer. The concept of analyzing genetic mutations in cancer at the individual level and selecting the best individualized treatment for that genetic mutation is called precision medicine for cancer.
Founded by Dr. Hua-Key Chen and Dr. Shu-Chen Chen, both former researchers at the National Institutes of Health and Chang Gung University in Taiwan, ACTG is a leading clinical sequencing company in Asia with its headquarters in Taiwan. The company is one of the top clinical sequencing companies in Asia, and has the advantage of having a large Asian-specific genetic information database and the ability to make appropriate diagnoses based on careful sample processing and accurate annotations. We are developing services that cover the entire spectrum of cancer patient care, from individual patient cancer risk assessment to treatment selection and post-treatment monitoring.
ACTG considers Japan as its most important partner in Asia and has been collaborating with Kyoto University in the development of cancer-specific tailor-made panels (diagnostic systems). In Japan, Canon Medical Systems Inc. and ACTG have established a joint venture (Canon Medical Systems 66.61 TP3T, ACTG 33.41 TP3T) to provide ACTMED's clinical sequence services in Japan.
Kyoto iCAP invested in ACTG jointly with three others in the hope that the company would contribute to improved outcomes for cancer patients, particularly in Asia, and that it would have a two-way ripple effect on research and business in personalized cancer care in Japan, particularly in Asia.

Overview of ACT Genomics Holdings Company Ltd.

Establishment	July 2014
Business	Precision medicine and cancer risk assessment through DNA sequencing-based technology
Head Office Location	Taipei City Lake District (registered address: British Cayman Islands)
President & CEO	Chen, Hua-kee